Lisata Therapeutics, Inc.
LSTA
$2.50
-$0.03-1.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.30% | -5.60% | -6.93% | -9.03% | -19.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.47% | -11.03% | -8.94% | -10.44% | -12.59% |
| Operating Income | 12.91% | 14.96% | 12.83% | 10.44% | 12.59% |
| Income Before Tax | 9.07% | 12.56% | 10.30% | 9.49% | 60.89% |
| Income Tax Expenses | -20.55% | 69.25% | 65.75% | 65.75% | 65.75% |
| Earnings from Continuing Operations | 10.19% | 3.72% | 4.10% | 3.38% | 60.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.19% | 3.72% | 4.10% | 3.38% | 60.68% |
| EBIT | 12.91% | 14.96% | 12.83% | 10.44% | 12.59% |
| EBITDA | 12.95% | 15.01% | 12.87% | 10.48% | 12.79% |
| EPS Basic | 12.92% | 6.53% | 7.05% | 6.53% | 74.14% |
| Normalized Basic EPS | 11.43% | 14.87% | 13.38% | 11.95% | 29.67% |
| EPS Diluted | 12.92% | 6.53% | 7.05% | 6.57% | 74.16% |
| Normalized Diluted EPS | 11.43% | 14.87% | 13.38% | 11.95% | 29.67% |
| Average Basic Shares Outstanding | 3.16% | 3.15% | 3.18% | 3.30% | 14.92% |
| Average Diluted Shares Outstanding | 3.16% | 3.15% | 3.18% | 3.30% | 14.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |